Freenome, Inc. Common stock (FRNM) 株式分析

Freenome, Inc. operates as a biotechnology company focused on developing blood-based tests for early cancer detection using artificial intelligence and multiomics technology. The company develops and provides blood-based tests for early cancer detection, including a test for colorectal cancer screening. It offers a multiomics platform that combines computational biology, machine learning, and multiple data types to identify biomarkers and detect various cancers. The company conducts clinical research programs, such as the PREEMPT CRC, Sanderson, and Vallania studies, to validate and expand its cancer detection tests to multiple cancer types. It collaborates with healthcare organizations and partners to advance clinical studies and enhance its product portfolio, including an autoantibody platform with additional biomarkers, and provides patient stratification and monitoring solutions using its multiomics technology. The company was founded in 2014 and is based in Brisbane, California.

企業説明は英語で表示されています。